Kobe University Repository : Kernel
タイトル
Title
Pathogenic evaluation of synonymous COL4A5 variants in X-linked
Alport syndrome using a minigene assay
著者
Author(s)
Horinouchi, Tomoko / Yamamura, Tomohiko / Minamikawa, Shogo /
Nagano, China / Sakakibara, Nana / Nakanishi, Koichi / Shima, Yuko /
Morisada, Naoya / Ishiko, Shinya / Aoto, Yuya / Nagase, Hiroaki /
Takeda, Hiroki / Rossanti, Rini / Ishimori, Shingo / Kaito, Hiroshi /
Matsuo, Masafumi / Iijima, Kazumoto / Nozu, Kandai
掲載誌・巻号・ページ
Molecular Genetics & Genomic Medicine,8(8):e1342
Citation
刊行日
Issue date
2020-08
資源タイプ
Resource Type
Journal Article / 学術雑誌論文
版区分
Resource Version
publisher
権利
Rights
© 2020 The Authors. Molecular Genetics & Genomic Medicine
published by Wiley Periodicals LLC. This is an open access article
under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
DOI
10.1002/mgg3.1342
JaLCDOI
URL
http://www.lib.kobe-u.ac.jp/handle_kernel/90007398
PDF issue: 2022-02-20
Received: 21 February 2020
DOI: 10.1002/mgg3.1342
|
Revised: 13 May 2020
|
Accepted: 19 May 2020
ORIGINAL ARTICLE
Pathogenic evaluation of synonymous COL4A5 variants in
X-linked Alport syndrome using a minigene assay
Tomoko Horinouchi1
| Tomohiko Yamamura1 | Shogo Minamikawa1 |
China Nagano1 | Nana Sakakibara1 | Koichi Nakanishi2 | Yuko Shima3 |
Naoya Morisada1 | Shinya Ishiko1 | Yuya Aoto1 | Hiroaki Nagase1 | Hiroki Takeda1
Rini Rossanti1 | Shingo Ishimori1 | Hiroshi Kaito1 |
Masafumi Matsuo4 | Kazumoto Iijima1 | Kandai Nozu1
|
1
Department of Pediatrics, Kobe University
Graduate School of Medicine, Kobe, Japan
2
Department of Child Health and Welfare
(Pediatrics), Graduate School of Medicine,
University of the Ryukyus, Nishihara, Japan
3
Department of Pediatrics, Wakayama
Medical University, Wakayama, Japan
4
Department of Physical Therapy, Faculty
of Rehabilitation, Kobe Gakuin University,
Kobe, Japan
Correspondence
Tomoko Horinouchi, Department of
Pediatrics, Kobe University Graduate
School of Medicine, 7-5-1 Kusunoki-cho,
Chuo, Kobe, Hyogo 650-0017, Japan.
Email: tohori@med.kobe-u.ac.jp
Funding information
Grants-in-Aid for Scientific Research
(KAKENHI) from the Ministry of
Education, Culture, Sports, Science
and Technology of Japan, Grant/Award
Number: 16K19642, 17H04189, 18K15712
and 19K08726; Japan Agency for Medical
Research and Development, Grant/Award
Number: JP19ek0109231h0003
Abstract
Background: X-linked Alport syndrome (XLAS) is a progressive, hereditary
glomerular nephritis of variable severity caused by pathogenic COL4A5 variants.
Currently, genetic testing is widely used for diagnosing XLAS; however, determining the pathogenicity of variants detected by such analyses can be difficult. Intronic
variants or synonymous variants may cause inherited diseases by inducing aberrant
splicing. Transcript analysis is necessary to confirm the pathogenicity of such variants, but it is sometimes difficult to extract mRNA directly from patient specimens.
Methods: In this study, we conducted in vitro splicing analysis using a hybrid minigene assay and specimens from three XLAS patients with synonymous variants
causing aberrant splicing, including previously reported pathogenic mutations in the
same codon. The variants were c.876 A>T (p.Gly292=), c.2358 A>G (p.Pro786=),
and c.3906 A>G (p.Gln1302=).
Results: The results from our hybrid minigene assay were sufficient to predict splicing abnormalities; c.876 A>T cause 17-bp del and 35-bp del, c.2358 A>G cause
exon 29 skipping, c.3906 A>G cause exon 42 skipping, which are very likely to
cause pathogenicity. Further, patients carrying c.2358 A>G exhibited a mild phenotype that may have been associated with the presence of both normal and abnormally
spliced transcripts.
Conclusion: The minigene system was shown to be a sensitive assay and a useful
tool for investigating the pathogenicity of synonymous variants.
KEYWORDS
aberrant splicing, mild phenotype, splicing assay, synonymous variant, X-linked Alport syndrome
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Mol Genet Genomic Med. 2020;8:e1342.
https://doi.org/10.1002/mgg3.1342
wileyonlinelibrary.com/journal/mgg3
|
1 of 8
|
2 of 8
1
|
HORINOUCHI ET AL.
IN T RO D U C T ION
COL4A5 (MIM #303630) is a monogenic causative gene of
X-linked Alport syndrome (XLAS; MIM #301050), which
may cause end-stage renal disease accompanied by sensorineural hearing loss and ocular abnormalities (Barker
et al., 1990; Kashtan, 1998). COL4A5 encodes the collagen α5(IV) which constitute the glomerular basement
membrane (GBM), cochlea basement membrane, base
of the ocular lens, Bowman's capsule, and skin basement
membrane. COL4A5 mutations result in abnormal α5(IV)
expression, with a typically complete absence of α5(IV)
in men and a mosaic expression pattern in women (Nozu
et al., 2019). Males carrying hemizygous mutations exhibit more severe phenotypes than that of females with the
genotype-phenotype correlation in males with XLAS being
well established (Bekheirnia et al., 2010; Jais et al., 2000).
For instance, truncating mutations result in more severe phenotypes compared with that of non-truncating mutations,
such as missense mutations (Bekheirnia et al., 2010; Jais
et al., 2000). We previously reported that COL4A5 transcripts could also affect the severity of disease by aberrant
mRNA splicing resulting in truncation or non-truncation of
the gene product (Horinouchi et al., 2018). Recently, collateral with the progression of genetic analysis technology
such as comprehensive sequencing analysis using nextgeneration sequencing, the opportunity of genetic diagnosis has been rapidly increasing for cases in which XLAS
is suspected, including clinically mild cases. However, a
major problem is that many genomic DNA (gDNA) substitutions of unknown pathogenicity may be detected and
their pathogenicity must be assessed. In particular, when
intronic or synonymous variants are detected, many of
them are known to be nonpathogenic; however, it is important to consider the potential effect of splicing. This leads
to additional effort and cost that are needed to identify the
pathogenic variants that actually cause the aberrant splicing among many non-pathogenic variants. We believe that
variants with high allele frequencies are not likely to be
pathogenic. Therefore, only synonymous variants with low
allele frequencies (MAF < 0.1%) were evaluated for pathogenicity in this study.
Transcriptional analysis is often difficult to perform
as transcripts in the tissues may not be stable. In addition,
mRNA extracted from kidney is difficult to obtain in most
cases. With respect to COL4A5, peripheral blood leukocytes
express the transcripts and have been used as an alternative source for transcript analysis. However, it is still sometimes difficult to extract mRNA of sufficient quantity and
quality for successful analysis. Amplification of COL4A5
is also difficult when carrying the mutations that affect the
C-terminus or the N-terminus, which does not produce the
mRNA itself, or a mutation that cause mRNA disruption by a
nonsense-mediated decay. Some groups, including ours, have
reported the utility of minigene assays for predicting aberrant splicing in patients with Alport syndrome (Chiereghin
et al., 2017; Horinouchi et al., 2018; Malone, Funk, Alhamad,
& Miner, 2017). However, there remain insufficient data to
determine whether the minigene assay can serve as an alternative to analysis of patient mRNA. Furthermore, determination of the pathogenicity of synonymous COL4A5 variants
has currently not been reported. Here, we report on the evaluation of pathogenicity of synonymous COL4A5 variants detected in three patients with XLAS using minigene assays.
2
2.1
|
M ATERIAL S AND M ETHOD S
|
Patients
All procedures involving human participants in this study
were performed in accordance with the ethical standards of
the Institutional Review Board of Kobe University Graduate
School of Medicine and consistent with the 1964 Helsinki
Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study or from their parents or legal
guardians.
Patient 1, male, was 19 years old at the time of genetic
analysis. Microhematuria and proteinuria had been noted
for the patient from 3 years of age. Histological evaluation
of a kidney biopsy at 6 years of age revealed lamellation of
the GBM and negative expression of α3/α4/α5 (IV). The patient's disease developed into end-stage renal disease (ESRD)
at the age of 18 years. The patient's older brother had also
been diagnosed with hematuria and proteinuria at the age of
2 and had an estimated glomerular filtration rate (eGFR) of
32.4 mL/min/1.73 m2 at the age of 23. Their mother had hypertension, microhematuria, and proteinuria (0.2 g/g Cr) and
her eGFR was 60.7 mL/min/1.73 m2 at 49 years of age. None
of the family members had ocular abnormalities or hearing
loss. The clinical course and gene test results of this family
have been previously reported by our group (Fu et al., 2016).
Patient 2, male, was 43 years old at the time of genetic
analysis. He had been diagnosed with hematuria from childhood and proteinuria at 33 years of age. His condition developed into ESRD by the time of diagnosis. Evaluation of a
kidney biopsy revealed a thin basement membrane, but did
not show lamellation. Expression of α5 (IV) was positive.
This patient's younger brother had a similar clinical course
with hematuria from childhood, proteinuria from 20 years of
age, and an eGFR of 32 mL/min/1.73 m2 at 31 years of age
and their mother had hematuria. The brothers had neither ocular abnormalities nor hearing loss. The clinical courses of
siblings suggested that this family may have had relatively
mild phenotypes for male XLAS.
|
HORINOUCHI ET AL.
Patient 3, female, was 56 years old at the time of genetic
analysis. She had microhematuria and occasional proteinuria from 12 years of age. At the age of 30, she presented
with gross hematuria with tonsillitis. At 55, a kidney biopsy was performed due to elevated serum creatinine levels.
Histological analysis of the biopsy revealed a thin basement
membrane and mosaic pattern of α5 expression. At the time
genetic testing was performed, her serum creatinine had risen
to 1.34 mg/dL, and her eGFR was 32.8 mL/min/1.73 m2. She
was diagnosed with myopia, but not with other eye disorders or hearing loss. Her mother and younger brother and his
daughter had hematuria, but their genetic testing has not been
performed, and the detailed clinical course was unknown.
2.2
|
gDNA analysis
Total gDNA was isolated from patients’ peripheral blood
leukocytes using a QuickGene Mini-80 System (Kurabo
Industries Ltd.) according to the manufacturer's instructions.
For Patient 1, we performed conventional direct sequencing
of all exons and exon-intron boundaries in COL4A5 (NM:
000495.4) using the Sanger method. For Patients 2 and 3,
targeted next-generation sequencing was performed as described previously using a custom disease panel that included
COL4A3, COL4A4, and COL4A5 (Hashimura et al., 2014;
Horinouchi et al., 2018; Nozu et al., 2014).
2.3
|
mRNA analysis
For reverse transcription polymerase chain reaction
(RT-PCR) amplification of mRNA and direct sequencing,
total RNA was isolated from peripheral leukocytes using
RNAlater RNA Stabilization Reagent (Qiagen Inc.) and the
RNA was then reverse transcribed into complementary DNA
(cDNA) using an EcoDry Kit (Clontech Laboratories, Inc.).
RNA from urine sediments were isolated as previously described (Fu et al., 2016; Kaito et al., 2007).
2.4
|
Minigene splicing assays
Hybrid minigene constructs were created in the H492 vector previously developed (Figure S1), which is based on
the pcDNA 3.0 Mammalian Expression Vector (Invitrogen;
Nozu et al., 2009). We cloned DNA fragments containing
exons and introns around the target COL4A5 variants from
the peripheral leukocytes of the three patients and wild-type
controls using In-Fusion Cloning methods and an HD Cloning
Kit (Takara Bio Inc.). To generate the insert fragments, PCR
reactions in a 40 μL volume included 100–300 ng of template
human gDNA, 20 μL of 2 × Gflex PCR Buffer, 0.25 μmol/L
3 of 8
of each primer, and Tks Gflex DNA Polymerase (Takara).
The thermal cycling profile included 1 minutes at 94°C, followed by 35 cycles at 98°C for 10 seconds, 60°C for 15 seconds, and 68°C for 30–60 seconds. The inserted sequences
are shown in Figure S2. The cloning was done in accordance
with the manufacturer's instructions.
To create the constructs used for examining aberrant
splicing caused by mutations at the same codon, we cloned
wild-type gDNA and then, introduced mutations by sitedirected mutagenesis using a PrimeSTAR Mutagenesis Basal
Kit (Takara Bio Inc.), in accordance with the manufacturer's
instructions. The primers used are shown in Table S1.
The hybrid minigenes were confirmed by sequencing before transfection into HEK293T cells using Lipofectamine®
2000 (Thermo Fisher Scientific). HEK293T cells were
obtained from the Riken Bio Resource Center Cell Bank
(Tsukuba). Total RNA was extracted from cells after 24 hours
using an RNeasy® Plus Mini Kit (Qiagen GmbH). An aliquot
of total RNA (1 μg) was reverse-transcribed using RNA to
cDNA EcoDry Premix (Double Primed) (Takara Bio Inc.).
PCR amplification was performed using a forward primer
corresponding to a segment upstream of exon A and a reverse primer complementary to a segment downstream of
exon B, as previously described (Nakanishi et al., 2019). PCR
products were analyzed by electrophoresis on an Agilent
2100 Bioanalyzer using an Agilent DNA1000 Kit (Agilent
Technologies), then directly sequenced.
|
2.5
In silico analysis
The splice sites of each variant were predicted using Human
Splicing Finder (http://www.umd.be/HSF3/).
3
|
RESULTS
3.1 | Synonymous variants detected in our
study
Patient 1 was hemizygous for a c.876 A>T (p.Gly292=) mutation in exon 15, as previously reported (Fu et al., 2016).
Single nucleotide substitutions c.2358 A>G (p.Pro786=)
in exon 29 and c.3906 A>G (p.Gln1302=) in exon 42 were
detected in Patient 2 and Patient 3, respectively (Table 1;
Figure 1). No other pathogenic variants were detected in the
three patients.
3.2
|
mRNA analysis of patient samples
For Patient 1, two variant transcripts were detected with
deletions of 35- and 17-bp c.876 A>T r.[857_891del,
|
r.[=, 3791_3924del]
r.[=, 3791_3924del]
N/A
N/A
c
N/A
No.3 (Cheong
et al.)c
Heiskari N, Zhang X, Zhou J, Leinonen A, Barker D, Gregory M, et al. J Am Soc Nephrol. 1996;7:702–9.
56
Patient 3 (A514)
Barker DF, Denison JC, Atkin CL, Gregory MC. Am J Med Gen. 2001;98:148–60.
b
a
43
Patient 2 (A467)
Abbreviation: N/A, not available.
N/A
No.2 (Heiskari
et al.)b
Cheong HI, Park HW, Ha IS, Choi Y. Pediatr Nephrol (Berlin, Germany). 2000;14:117–21.
c.3904 C>T
p.Gln1302Term
ESRD as juvenile
N/A
N/A
No.1 (Barker et al.)a
N/A
Mosaic pattern of α5 (IV) expression
Thin basement membrane
eGFR = 32.8 mL/min/1.73 m2
Female
c.3906 A>G p.Gln1302=
r.[=, 2245_2395del]
r.[=, 2245_2395del]
Positive expression of α5 (IV)
Thin basement membrane
ESRD at 43 year
Male
c.2358 A>G p.Pro786=
r.=
N/A
ESRD at 15 year
Male
23
Patient 1 (A178)
MPGN-like (light microscopy only)
ESRD+ (Male patients in family)
Female
c.875 G>T p.Gly292Val
r.=
N/A
Lamellation of the GBM
Negative expression of α5 (IV)
eGFR = 32.4 mL/min/1.73 m2
Male
Age
(Year)
N/A
Kidney biopsy
Renal function
Sex
c.874 G>C p.Gly292Arg
r.[=, 875_891del,
857_891del]
r.[875_891del,
857_891del]
875_891del]. We had previously reported only a single transcript with a 35-bp deletion relative to wild-type transcripts
(Fu et al., 2016). For the current analysis, we resequenced the
PCR products to identify the deletions (Figure 2).
For Patient 2, transcripts skipping exon 29 were detected
in both the urine and peripheral blood leukocytes (Figure 2).
In addition to the truncated transcripts, a small amount of normally spliced transcript was detected in the urine (Figure 2)
(c.2358 A>G r.[=, 2245_2395del]). For Patient 3, COL4A5
transcripts could not be amplified for unknown reasons and
in vivo mRNA analysis results were not available.
3.3
Patient
Patients analyzed in this study and their characteristics
TABLE 1
c.876 A>T p.Gly292=
In vitro minigene
assay
mRNA analysis of
patient samples
HORINOUCHI ET AL.
gDNA substitution
4 of 8
|
In vitro splicing
Assays using the minigene system were performed using
gDNA fragments from all three patients. In addition, three
previously reported pathogenic variants at the same codon
(two for Patient 1 and one for Patient 3; Barker, Denison,
Atkin, & Gregory, 2001; Cheong, Park, Ha, & Choi, 2000;
Heiskari et al., 1996) were analyzed using the minigene system (Table 1).
For Patient 1 and reported variants (No. 1 and No. 2, respectively), we cloned introns 13 to 16 of COL4A5. For Patient
2, we cloned COL4A5 introns 28 and 29. For Patient 3 and one
reported variant (No. 3), we cloned COL4A5 introns 41 and
42. Patient 1's minigene expressed both full-length and 17-bp
deletion transcripts, as well as a possible 35-bp deletion transcript (c.876 A>T r.[=, 875_891del, 857_8921del). The two
reported missense variants (Nos. 1 and 2) produced only fulllength transcripts (c.874 G>C r.=, c.875 G>T r=). Patient 2’s
minigene primarily expressed a transcript that skipped exon
29, but a few canonical transcripts were also detected (c.2358
A>G r.[=, 2245_2395del]). Patient 3’s minigene expressed
more transcripts that skipped exon 42 than did a wild-type
control minigene (c.3906 A>G r.[=, 3791_3924del]). A minigene from a patient with a nonsense mutation reported by
Cheong et al. (Cheong et al., 2000) (No. 3) also expressed a
transcript that skipped exon 42, which was expressed at a level
higher than normal, but lower than that of Patient 3 (c. 3904
C>T r.[=, 3791_3924del]; Figure 3; Figure S3).
3.4
|
In silico splicing assay
The donor site scores for variants No. 1 (c.874 G>C), No.
2 (c.875 G>T), and Patient 1 (c.876 A>T) are shown in
Figure S4. The synonymous mutation c.876 A>T created a
novel donor site (MaxEnt score 9.6) while neither variant No.
1 nor No. 2 exhibited this novel donor site. The original donor
site MaxEnt score was 9.35. Therefore, the novel donor site
was stronger than the original. The donor site for the 35-bp
deletion observed in vivo also showed a relatively high score
|
HORINOUCHI ET AL.
(a)
c.876 A>T
(b)
c.2358 A>G
Int
Exon29
Int
Exon15
5 of 8
Pt
Pt
Bro
Mo
(c)
c.3906 A>G
Exon42
Int
Bro
Pt
F I G U R E 1 Nucleotide changes in COL4A5 in patients with X-linked Alport syndrome. (a) Patient 1 and his brother carried the hemizygous
mutation and their mother carried the heterozygous mutation c.876A>T, 16 bp upstream of the exon 15 splice donor site. (b) Patient 2 and his
brother carried the hemizygous mutation c.2358 A>G, 38 bp upstream of the exon 29 splice donor site. (c) Patient 3 carried the heterozygous
mutation c.3906 A>G, 19 bp upstream of the exon 42 splice donor site. Pt, patient; Mo, mother; Bro, brother; Int, intron
Exon14
Exon15
Exon14
Exon15
Exon15
Exon16
(a) (Pt 1)
c.876 A>T
WT
Pt
WT
blood Urine
Pt
1353bp
1078bp
872bp
603bp
Exon15
Exon16
Pt
Blood
310bp
Exon15
Exon14
Exon16
Pt
Blood
Pt
Urine
(b) (Pt 2)
c.2358 A>G
WT
1353bp
1078bp
872bp
603bp
Pt
Pt
blood Urine
Exon28
Exon29
Exon29
Exon30
WT
Pt
Urine
Pt
Blood
Pt
Urine
Exon28
Exon30
F I G U R E 2 mRNA analysis of specimens from patients with X-linked Alport syndrome. (a) An isoform with 17-bp deletion was detected from
the blood sample of Patient 1 and a 35-bp isoform deletion was detected from blood and urine samples. (b) An isoform exhibiting exon 29 skipping was
detected in the blood sample from Patient 2 while a small amount of canonical isoform was also detected in the urine sample. Pt, patient; WT, wild-type
(8.68). For Patient 2 (c.2358 A>G) and Patient 3 (c.3906
A>G), both synonymous mutations failed to alter donor site
scores. Furthermore, no novel donor sites were created.
In Patients 2 and 3, alteration of an exonic splicing enhancer site and potential alteration of splicing were demonstrated by the Human Splicing Finder. However, it was
|
6 of 8
HORINOUCHI ET AL.
difficult to determine which motifs are directly related, because binding affinities for multiple splicing enhancers and
silencers can change. This may reflect the fact that these programs are primarily used for screening and are more difficult
to use to support functional analysis. Interestingly, the possibility that nonsense mutation c.3904 C>T p.Gln1302Term,
in the same codon as variant No. 3, results in aberrant splicing has previously been reported based on extensive in silico
analysis (Xiong et al., 2015).
4
|
D IS C U SS ION
This is the first report evaluating the pathogenicity of synonymous variants in COL4A5 using an in vitro splicing assay.
Our data show that this minigene system works well for the
determination of the impact of variants on splicing.
Patient 1 presented with typical Alport syndrome and was
considered to be a relatively severe case. Only transcripts
with 17- or 35-bp deletions were identified in the urine and
peripheral blood from this patient, both of which were out of
frame. In addition to canonical transcripts and several other
nonspecific bands, in vitro analysis using the minigene system identified transcripts that appeared to contain a 17-bp
deletion and possibly a 35-bp deletion. The reason for this
discrepancy depends on cell type-specific alternative splicing
and the conditions at the time of mRNA extraction; for example, the destruction of mRNA by nonsense-mediated decay
could cause the inconsistency (Acedo et al., 2015). As shown
by in silico analysis, this variability may have been due to the
mutation creating a novel donor site whose score was higher
than that of the original donor site. Moreover, two mutations
reported as missense mutations within the same codon failed
c.876 A>T c.874 G>C c.875 G>T
A
A
to induce aberrant splicing in vitro. In silico analysis showed
no significant new splice donor sites. This is consistent with
these two mutations being simple missense mutations. The
detection of normally spliced transcripts from the patient's
variant minigene may be a limitation of this in vitro splicing
assay.
Patient 2 had a relatively mild case of Alport syndrome,
even though he had a COL4A5 transcript that skipped exon
29 (151 bp), which also resulted in a frameshift. The reason
for only mild presentation of disease symptoms in this patient
may have been due to the small amount of full-length transcript still being transcribed/spliced, as detected in the urine
sediments.
By the in vitro splicing assay, Patient 3 expressed transcripts that skipped exon 42 (134 bp), but direct mRNA analysis could not be performed on the specimens collected from
this patient. It is not uncommon to encounter such a situation
in clinical practice. In such cases, if gDNA testing reveals
only synonymous variants, a genetic diagnosis of Alport syndrome cannot be made using the usual methods. It is also
an inevitable limitation that when analyzing exons, we must
consider the possibility that deep intronic mutations could
change splicing. In the case of Patient 3, a nonsense mutation
in the same codon (c.3904 C>T p.Gln1302Term) has been
reported to be associated with a splicing alteration (Xiong
et al., 2015). Although we were not able to perform direct
mRNA analysis on the patient specimens, our minigene assay
revealed that exon 42 skipping was more likely to occur in
the order of synonymous mutation, nonsense mutation, and
wild type. Based on the previous report and the current results of our minigene assay from this study, we conclude that
this synonymous variant should be considered to be causative
for Alport syndrome.
c.2358 A>G
Ex
14
Ex
14
Ex
15
Ex
15
Ex
16
Ex
16
c.3906 A>G c.3904 C>T
B
A
Ex
29
A
B
B
A
Ex
42
A
B
B
B
17-bp del
WT Pt 1 No. 1 No. 2
WT Pt 2
WT Pt 3 No.3
F I G U R E 3 Reverse transcription polymerase chain reaction amplified products of minigene transcripts. Patient 1 (Pt 1) expressed transcripts
with a 17-bp deletion, canonical transcripts, and multiple thin bands that could not be sequenced. Variant No. 1 and No. 2 expressed only canonical
transcripts. Patient 2 (Pt 2) expressed mainly transcripts exhibiting exon 29 skipping and a few full-length transcripts. Patient 3 (Pt 3) expressed
transcripts exhibiting exon 42 skipping, which was most likely to occur in the synonymous mutation (Pt 3), followed by the nonsense mutation
(No. 3), then the control sequence (WT), and least likely to occur in the full-length transcript. Pt, patient; WT, wild-type
|
HORINOUCHI ET AL.
In the current study, we determined that our minigene
approach was applicable for detecting and analyzing synonymous and missense mutations in COL4A5. It may also be
useful for predicting splicing stability. However, an important
limitation of this minigene system is that it showed exon skipping even with the WT control sequence (Figure 3, WT for
Pt 2 and 3). This system overexpresses mRNA synthesis and
is likely too sensitive, so exon skipping is observed even with
WT control constructs. Therefore, as specimens can only be
compared and contrasted with control sequences, it may be
difficult to predict the extent of phenotypic rescue due to
the presence of a canonical transcript. Considering that transcripts are often unstable and difficult to obtain from patients
in sufficient quantity and quality and that alternative splicing
may occur in different organs, this minigene system, which
can reproduce the splicing patterns of RNA samples from
patients that carry spliceogenic variants, may prove very
useful as previously described (Acedo et al., 2015; FraileBethencourt et al., 2017; Fraile-Bethencourt et al., 2019). We
believe that in vitro splicing assays using the minigene system will become more practical in the future.
Recently, a wide spectrum of collagen IV-related renal
disease has attracted attention and the concept of Alport
syndrome is changing (Kashtan et al., 2018). With technical advances in genetic analysis, COL4A5 has also been increasingly identified in patients with chronic kidney disease
(Cameron-Christie et al., 2019; Gast et al., 2016). In addition, like COL4A5 coding type IV collagen, COL4A3 traditionally causes autosomal dominant Alport syndrome and is
reported to change susceptibility to diabetic kidney disease
(Miner, 2019; Salem et al., 2019). We showed that splicing
abnormalities may cause severe disease, whereas the presence of full-length transcripts may attenuate the effect, resulting in milder disease. It is important to recognize splicing
alterations as one mechanism that may contribute to the development of “mild” disease.
In conclusion, we presented three cases in which synonymous variants resulted in abnormal splicing leading
to the development of disease. The disease severity varied
and was milder when normal COL4A5 transcripts persisted.
Furthermore, mild cases may have different clinical courses
from those seen for typical Alport syndrome. The minigene
system described was shown to be a sensitive and useful tool
for investigating whether synonymous variants cause splicing
abnormalities.
ACKNOWLEDGMENTS
This study was supported by Grants-in-Aid for Scientific
Research (KAKENHI) from the Ministry of Education,
Culture, Sports, Science and Technology of Japan (subject ID: 18K15712 to Tomoko Horinouchi, 19K08726
to Kandai Nozu, 16K19642 to Tomohiko Yamamura,
and 17H04189 to Kazumoto Iijima), and by AMED
7 of 8
(Grant Number: JP19ek0109231h0003 to Kandai Nozu and
Kazumoto Iijima).
CONFLICT OF INTEREST
Kazumoto Iijima has received grant support from Daiichi
Sankyo Co., Ltd., and consulting fees from Takeda
Pharmaceutical Co., Ono Pharmaceutical Co. Ltd.,
Boehringer Ingelheim, Astellas Pharma Inc., and Kyowa
Kirin Co., Ltd. Kandai Nozu has received lecture fees from
Novartis Pharmaceuticals Corporation and consulting fees
from Kyowa Kirin Co., Ltd. Kazumoto Iijima and Kandai
Nozu have filed a patent application on the development of
antisense nucleotides for exon skipping therapy in Alport
syndrome.
AUTHOR CONTRIBUTIONS
T.H. designed the study concept and wrote the manuscript.
Ka.N. interpreted the data and wrote the manuscript. T.Y.,
S.M., C.N., N.S., N.M., Shinya.I., Y.A., and R.R. established
and conducted molecular analysis and interpreted the data.
M.M. established the minigene assay. Ko.N., Y.S., H.N.,
H.T., Shingo.I., H.K., and K.I. critically reviewed the manuscript. All authors read and approved the final version of the
manuscript.
DATA AVAILABILIT Y STATEMENT
The datasets generated and/or analyzed during the current
study are available from the corresponding author on reasonable request.
ORCID
https://orcid.
Tomoko Horinouchi
org/0000-0003-1655-6030
Kandai Nozu
https://orcid.org/0000-0002-0290-3137
R E F E R E NC E S
Acedo, A., Hernández-Moro, C., Curiel-García, Á., Díez-Gómez, B.,
& Velasco, E. A. (2015). Functional classification of BRCA2 DNA
variants by splicing assays in a large minigene with 9 exons. Human
Mutation, 36(2), 210–221. https://doi.org/10.1002/humu.22725
Barker, D. F., Denison, J. C., Atkin, C. L., & Gregory, M. C. (2001).
Efficient detection of Alport syndrome COL4A5 mutations with
multiplex genomic PCR-SSCP. American Journal of Medical
Genetics, 98(2), 148–160. https://doi.org/10.1002/1096-8628(20010
115)98:2<148:aid-ajmg1024>3.0.co;2-w
Barker, D. F., Hostikka, S. L., Zhou, J., Chow, L. T., Oliphant, A. R.,
Gerken, S. C. … Tryggvason, K. (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science
(New York, NY), 248(4960), 1224–1227. https://doi.org/10.1126/
science.2349482
Bekheirnia, M. R., Reed, B., Gregory, M. C., McFann, K., Shamshirsaz,
A. A., Masoumi, A., & Schrier, R. W. (2010). Genotype-phenotype
correlation in X-linked Alport syndrome. Journal of the American
Society of Nephrology: JASN, 21(5), 876–883. https://doi.
org/10.1681/asn.2009070784
8 of 8
|
Cameron-Christie, S., Wolock, C. J., Groopman, E., Petrovski, S.,
Kamalakaran, S., Povysil, G., … Gharavi, A. G. (2019). Exomebased rare-variant analyses in CKD. Journal of the American Society
of Nephrology: JASN, 30(6), 1109–1122. https://doi.org/10.1681/
asn.2018090909
Cheong, H. I., Park, H. W., Ha, I. S., & Choi, Y. (2000). Mutational
analysis of COL4A5 gene in Korean Alport syndrome. Pediatric
Nephrology (Berlin, Germany), 14(2), 117–121. https://doi.
org/10.1007/s004670050025
Chiereghin, C., Robusto, M., Mastrangelo, A., Castorina, P., Montini,
G., Giani, M., … Soldà, G. (2017). Alport syndrome cold cases:
Missing mutations identified by exome sequencing and functional
analysis. PLoS One, 12(6), e0178630. https://doi.org/10.1371/journ
al.pone.0178630
Fraile-Bethencourt, E., Díez-Gómez, B., Velásquez-Zapata, V., Acedo,
A., Sanz, D. J., & Velasco, E. A. (2017). Functional classification
of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18. PLoS Genetics, 13(3),
e1006691. https://doi.org/10.1371/journal.pgen.1006691
Fraile-Bethencourt, E., Valenzuela-Palomo, A., Díez-Gómez, B., Goina,
E., Acedo, A., Buratti, E., & Velasco, E. A. (2019). Mis-splicing
in breast cancer: Identification of pathogenic BRCA2 variants by
systematic minigene assays. The Journal of Pathology, 248(4), 409–
420. https://doi.org/10.1002/path.5268
Fu, X. J., Nozu, K., Eguchi, A., Nozu, Y., Morisada, N., Shono, A., …
Iijima, K. (2016). X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type
IV collagen alpha chain 5 gene. Clinical and Experimental Nephrology,
20(5): 699–702. https://doi.org/10.1007/s10157-015-1197-9
Gast, C., Pengelly, R. J., Lyon, M., Bunyan, D. J., Seaby, E. G., Graham,
N. … Ennis, S. (2016). Collagen (COL4A) mutations are the most
frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrology, Dialysis, Transplantation: Official Publication of
the European Dialysis and Transplant Association – European Renal
Association, 31(6), 961–970. https://doi.org/10.1093/ndt/gfv325
Hashimura, Y., Nozu, K., Kaito, H., Nakanishi, K., Fu, X. J., Ohtsubo, H.,
… Morisada, N. (2014). Milder clinical aspects of X-linked Alport
syndrome in men positive for the collagen IV alpha5 chain. Kidney
International, 85(5), 1208–1213. https://doi.org/10.1038/ki.2013.479
Heiskari, N., Zhang, X., Zhou, J., Leinonen, A., Barker, D., Gregory,
M., … Grönhagen-Riska, C. (1996). Identification of 17 mutations
in ten exons in the COL4A5 collagen gene, but no mutations found
in four exons in COL4A6: A study of 250 patients with hematuria
and suspected of having Alport syndrome. Journal of the American
Society of Nephrology: JASN, 7(5), 702–709.
Horinouchi, T., Nozu, K., Yamamura, T., Minamikawa, S., Omori, T.,
Nakanishi, K., … Iijima, K. (2018). Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport
syndrome. Journal of the American Society of Nephrology: JASN,
29(8), 2244–2254. https://doi.org/10.1681/asn.2018030228
Jais, J. P., Knebelmann, B., Giatras, I., De Marchi, M. A. R. I. O.,
Rizzoni, G., Renieri, A. … Pirson, Y. (2000). X-linked Alport syndrome: Natural history in 195 families and genotype- phenotype correlations in males. Journal of the American Society of Nephrology:
JASN, 11(4), 649–657.
Kaito, H., Nozu, K., Fu, X. J., Kamioka, I., Fujita, T., Kanda, K., …
Matsuo, M. (2007). Detection of a transcript abnormality in mRNA
of the SLC12A3 gene extracted from urinary sediment cells of a
patient with Gitelman's syndrome. Pediatric Research, 61(4), 502–
505. https://doi.org/10.1203/pdr.0b013e318031935a
HORINOUCHI ET AL.
Kashtan, C. E. (1998). Alport syndrome and thin glomerular basement
membrane disease. Journal of the American Society of Nephrology:
JASN, 9(9), 1736–1750.
Kashtan, C. E., Ding, J., Garosi, G., Heidet, L., Massella, L., Nakanishi, K.,
… Gross, O. (2018). Alport syndrome: A unified classification of genetic disorders of collagen IV alpha345: A position paper of the Alport
Syndrome Classification Working Group. Kidney International, 93(5),
1045–1051. https://doi.org/10.1016/j.kint.2017.12.018
Malone, A. F., Funk, S. D., Alhamad, T., & Miner, J. H. (2017). Functional
assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in
X-linked Alport syndrome. Pediatric Nephrology (Berlin, Germany),
32(6), 997–1003. https://doi.org/10.1007/s00467-016-3565-4
Miner, J. H. (2019). Type IV collagen and diabetic kidney disease. Nature
Reviews Nephrology. https://doi.org/10.1038/s41581-019-0229-1
Nakanishi, K., Okamoto, T., Nozu, K., Hara, S., Sato, Y., Hayashi,
A., … Iijima, K. (2019). Pair analysis and custom array CGH can
detect a small copy number variation in COQ6 gene. Clinical and
Experimental Nephrology, 23(5), 669–675. https://doi.org/10.1007/
s10157-018-1682-z
Nozu, K., Iijima, K., Kawai, K., Nozu, Y., Nishida, A., Takeshima,
Y., … Matsuo, M. (2009). In vivo and in vitro splicing assay of
SLC12A1 in an antenatal salt-losing tubulopathy patient with an
intronic mutation. Human Genetics, 126(4), 533–538. https://doi.
org/10.1007/s00439-009-0697-7
Nozu, K., Nakanishi, K., Abe, Y., Udagawa, T., Okada, S., Okamoto, T., …
Iijima, K. (2019). A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clinical and Experimental Nephrology,
23(2), 158–168. https://doi.org/10.1007/s10157-018-1629-4
Nozu, K., Vorechovsky, I., Kaito, H., Fu, X. J., Nakanishi, K.,
Hashimura, Y., … Imasawa, T. (2014). X-linked Alport syndrome
caused by splicing mutations in COL4A5. Clinical Journal of the
American Society of Nephrology: CJASN, 9(11), 1958–1964. https://
doi.org/10.2215/cjn.04140414
Salem, R. M., Todd, J. N., Sandholm, N., Cole, J. B., Chen, W.-M.,
Andrews, D., … Florez, J. C. (2019). Genome-wide association
study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. Journal of the American
Society of Nephrology: JASN, 30(10), 2000–2016. https://doi.
org/10.1681/asn.2019030218
Xiong, H. Y., Alipanahi, B., Lee, L. J., Bretschneider, H., Merico,
D., Yuen, R. K., … Morris, Q. (2015). RNA splicing. The human
splicing code reveals new insights into the genetic determinants of
disease. Science (New York, NY), 347(6218), 1254806. https://doi.
org/10.1126/science.1254806
SUPPORTING INFORMATION
Additional Supporting Information may be found online in
the Supporting Information section.
How to cite this article: Horinouchi T, Yamamura T,
Minamikawa S, et al. Pathogenic evaluation of
synonymous COL4A5 variants in X-linked Alport
syndrome using a minigene assay. Mol Genet Genomic
Med. 2020;8:e1342.
https://doi.org/10.1002/mgg3.1342